Cargando…

C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk

Growing evidence points to a role for inflammation in prostate carcinogenesis. The significance of C-reactive protein (CRP), an inflammatory and innate immunity molecule, has not been evaluated thoroughly in prostate cancer (PC). In this study of 739 Finnish patients with PC and 760 healthy men, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Eklund, C M, Tammela, T L J, Schleutker, J, Hurme, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714238/
https://www.ncbi.nlm.nih.gov/pubmed/19436291
http://dx.doi.org/10.1038/sj.bjc.6605081
_version_ 1782169654762930176
author Eklund, C M
Tammela, T L J
Schleutker, J
Hurme, M
author_facet Eklund, C M
Tammela, T L J
Schleutker, J
Hurme, M
author_sort Eklund, C M
collection PubMed
description Growing evidence points to a role for inflammation in prostate carcinogenesis. The significance of C-reactive protein (CRP), an inflammatory and innate immunity molecule, has not been evaluated thoroughly in prostate cancer (PC). In this study of 739 Finnish patients with PC and 760 healthy men, we evaluated the associations of CRP genotypes and haplotypes with total PC risk and PC progression, using prostate-specific antigen (PSA) as a marker of metastatic disease. Although the haplotype frequencies were similar in patients and controls, an association between haplotype ACCCA and patients' PSA levels was found. The carriers more often had a high PSA than non-carriers (P=0.0002) and the SNP rs2794521 A-allele and rs1800947 C-allele carriers had a higher PSA than non-carriers (P=0.009 and P=0.0004, respectively). A trend for a younger age at diagnosis was found among the carriers of ACCCA (P=0.07) and the rs1800947 C-allele (P=0.06), as well as a trend for the latter to have more likely metastases (P=0.06), but not after Bonferroni correction (α=0.00208). This is the first study to suggest association between PSA and CRP variants in PC and, therefore, further studies are warranted. CRP alleles previously found to protect against increased CRP levels are now suggested to be associated with metastatic PC, indicated by elevated PSA.
format Text
id pubmed-2714238
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27142382010-06-16 C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk Eklund, C M Tammela, T L J Schleutker, J Hurme, M Br J Cancer Clinical Study Growing evidence points to a role for inflammation in prostate carcinogenesis. The significance of C-reactive protein (CRP), an inflammatory and innate immunity molecule, has not been evaluated thoroughly in prostate cancer (PC). In this study of 739 Finnish patients with PC and 760 healthy men, we evaluated the associations of CRP genotypes and haplotypes with total PC risk and PC progression, using prostate-specific antigen (PSA) as a marker of metastatic disease. Although the haplotype frequencies were similar in patients and controls, an association between haplotype ACCCA and patients' PSA levels was found. The carriers more often had a high PSA than non-carriers (P=0.0002) and the SNP rs2794521 A-allele and rs1800947 C-allele carriers had a higher PSA than non-carriers (P=0.009 and P=0.0004, respectively). A trend for a younger age at diagnosis was found among the carriers of ACCCA (P=0.07) and the rs1800947 C-allele (P=0.06), as well as a trend for the latter to have more likely metastases (P=0.06), but not after Bonferroni correction (α=0.00208). This is the first study to suggest association between PSA and CRP variants in PC and, therefore, further studies are warranted. CRP alleles previously found to protect against increased CRP levels are now suggested to be associated with metastatic PC, indicated by elevated PSA. Nature Publishing Group 2009-06-16 2009-05-12 /pmc/articles/PMC2714238/ /pubmed/19436291 http://dx.doi.org/10.1038/sj.bjc.6605081 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Eklund, C M
Tammela, T L J
Schleutker, J
Hurme, M
C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk
title C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk
title_full C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk
title_fullStr C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk
title_full_unstemmed C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk
title_short C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk
title_sort c-reactive protein haplotype is associated with high psa as a marker of metastatic prostate cancer but not with overall cancer risk
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714238/
https://www.ncbi.nlm.nih.gov/pubmed/19436291
http://dx.doi.org/10.1038/sj.bjc.6605081
work_keys_str_mv AT eklundcm creactiveproteinhaplotypeisassociatedwithhighpsaasamarkerofmetastaticprostatecancerbutnotwithoverallcancerrisk
AT tammelatlj creactiveproteinhaplotypeisassociatedwithhighpsaasamarkerofmetastaticprostatecancerbutnotwithoverallcancerrisk
AT schleutkerj creactiveproteinhaplotypeisassociatedwithhighpsaasamarkerofmetastaticprostatecancerbutnotwithoverallcancerrisk
AT hurmem creactiveproteinhaplotypeisassociatedwithhighpsaasamarkerofmetastaticprostatecancerbutnotwithoverallcancerrisk